Skip to main content

Table 2 Comparison of clinico-pathological variables between TNBC and non-TNBC patients overexpressing or not BRCA1-IRIS (aka IRIS)

From: The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion

Menopausal

IRIS-positive

IRIS-negative

χ2

P-value

Total

Pre

TNBC

14 (74%)

TNBC

5 (26%)

6.15

0.013

19

 

Non-TNBC

9 (36%)

Non-TNBC

16 (64%)

 

25

Post

TNBC

14 (58%)

TNBC

10 (42%)

7.44

0.0064

24

 

Non-TNBC

6 (21%)

Non-TNBC

22 (79%)

 

28

Total

 

43

 

53

  

96

Tumor size

IRIS-positive

IRIS-negative

χ2

P-value

 

≤5 cm

TNBC

21 (91%)

TNBC

2 (9%)

28.46

<0.000001

23

 

Non-TNBC

9 (22%)

Non-TNBC

32 (78%)

 

41

>5 cm

TNBC

12 (60%)

TNBC

8 (40%)

0.31

0.5809

20

 

Non-TNBC

6 (50%)

Non-TNBC

6 (50%)

 

12

Total

 

43

 

53

  

96

Grade

IRIS-positive

IRIS-negative

χ2

P-value

 

1 + 2

TNBC

23 (70%)

TNBC

10 (30%)

13.84

0.0002

33

 

Non-TNBC

13 (28%)

Non-TNBC

34 (72%)

 

47

3

TNBC

5 (62%)

TNBC

3 (38%)

0.63

0.4285

8

 

Non-TNBC

2 (40%)

Non-TNBC

3 (60%)

 

5

Total

 

43

 

50

  

93

Stage

IRIS-positive

IRIS-negative

χ2

P-value

 

II

TNBC

8 (80%)

TNBC

2 (20%)

7.25

0.0071

10

 

Non-TNBC

9 (31%)

Non-TNBC

20 (69%)

 

29

III + IV

TNBC

16 (67%)

TNBC

8 (33%)

7.14

0.0075

24

 

Non-TNBC

6 (27%)

Non-TNBC

16 (73%)

 

22

Total

 

39

 

46

  

85

Lymph-node

IRIS-positive

IRIS-negative

χ2

P-value

 

Present

TNBC

25 (76%)

TNBC

8 (24%)

17.28

<0.000001

33

 

Non-TNBC

7 (23%)

Non-TNBC

23 (77%)

 

30

Absent

TNBC

4 (40%)

TNBC

6 (60%)

0.29

0.5922

10

 

Non-TNBC

7 (30%)

Non-TNBC

16 (70%)

 

23

Total

 

43

 

53

  

96